BSX vs MDT vs SYK: MedTech Earnings Preview as Q4 Results Put Growth and Margins in Focus
Key Takeaways
-
Boston Scientific (BSX) reports Q4 2025 earnings on February 4, with consensus expecting $0.78 adjusted EPS on $5.27B revenue, in line with guidance of $0.77–$0.79 EPS and 11–13% organic growth.
-
Medtronic (MDT) posted strong Q2 FY26 results: $9B revenue (+5.5% organic), $1.36 adjusted EPS, raising FY26 guidance amid pulsed field ablation momentum. Q3 FY26 results are expected February 17.
-
Stryker (SYK) delivered record Q4/FY 2025 results: $7.17B Q4 revenue (+11% organic), $4.47 adjusted EPS; FY sales topped $25B with 2026 guidance of 8–9.5% organic growth.
-
BSX leads in cardiovascular and MedSurg growth, while MDT and SYK focus on stable margins and capital equipment strength.
-
All three benefit from procedural volume recovery, though tariff headwinds (~$185–$400M impact) loom for 2026.
-
Investor focus: BSX’s strong beat history (~7% average) vs. peers’ raised outlooks signals competitive positioning.
Why This Comparison Matters
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
MDT’s ablation surge and SYK’s Mako robotics dominance illustrate trade-offs between growth and scale. Combined, the trio represents ~$300B in market capitalization, offering investors insight into cardiovascular, orthopedics, and surgical trends amid 8–10% industry growth forecasts.
BSX Earnings Focus
-
Revenue: $5.27B (+15.6% YoY, 11–13% organic per guidance)
-
Adjusted EPS: $0.78 (+11% YoY), within company guidance of $0.77–$0.79
-
Key drivers:
-
Cardiovascular (~65% revenue): FARAPULSE PFA, WATCHMAN FLX
-
MedSurg: Neuromodulation post-Axonix
-
U.S. revenue: ~$3.39B expected (+17%)
-
-
Other metrics: Margin pressure from tariffs, historical EPS beats ~7.36% average, FY25 EPS raised to $3.02–$3.04
-
Stock reaction: Historically +3–4% on positive surprises
MDT Earnings/Business Context
-
Q2 FY26 results: $9B revenue (+5.5% organic), $1.36 adjusted EPS (+8%)
-
Cardiac ablation: 71% growth (U.S. PFA +128%)
-
FY26 guidance: 5.5% organic revenue growth, EPS $5.62–$5.66
-
Margins: Adjusted gross margin +70bps to 65.9%
-
Risks: Tariff impacts (~$185M FY26), China VBP pressures
-
Outlook: Scale and diversification provide stability vs. BSX’s higher-growth trajectory
SYK Earnings/Business Context
-
Q4/FY 2025 results: $7.17B Q4 revenue (+11% organic), $4.47 adjusted EPS (+11.5%); FY $25.12B revenue (+10.3% organic), $13.63 EPS (+11.8%)
-
Margins: Adjusted operating margin +100bps to 26.3%; free cash flow 81% of adjusted net earnings
-
2026 guidance: 8–9.5% organic growth, $14.90–$15.10 EPS
-
Drivers: Mako robotics (orthopedics), double-digit MedSurg/Neuro growth, vascular pressures manageable
-
Risks: Tariffs (~$400M), supply chain, orthopedics competition
-
Positioning: Procedural and capital equipment focus contrasts BSX’s interventional emphasis
AI Trading Bot Perspective
Tickeron offers AI-driven trading bots for BSX, MDT, and SYK:
-
BSX bot: Trend Trader for Broad Market Optimal Financial Fusion (60min FA), targeting large-cap trend momentum
-
MDT bot: Corridor TP-SL 2 AI Agent (60min), optimized for channel-based entries/exits
-
SYK bot: Trend Trader for Beginners (60min TA), ideal for orthopedic momentum plays
Historical performance varies by market conditions; these bots provide automated signals to complement manual analysis.
Key DriversCardio & MedSurgCardio & scaleOrtho/Capital equipment
-
BSX: High-growth cardiovascular, potential upside from historical beats
-
MDT: Broad therapy stability, slower growth but reliable margins
-
SYK: Ortho/surgical dominance with strong margin expansion
-
Risks: BSX procedure-sensitive; MDT China & tariffs; SYK supply/ortho competition
Investor sentiment tilts BSX for growth, peers for stability, reflecting trade-offs between upside potential vs. steady execution.
Tickeron AI Verdict
Tickeron’s AI models currently favor BSX pre-earnings, citing:
-
Superior trend stability
-
15%+ organic trajectory
-
Historical EPS beat consistency
MDT and SYK provide lower-volatility, steady profiles, but BSX holds a probabilistic edge if guidance is reaffirmed and tariffs remain manageable.
Disclaimers and Limitations
BSX in -5.26% downward trend, sliding for three consecutive days on March 04, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where BSX declined for three days, in of 268 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on March 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BSX as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Aroon Indicator for BSX entered a downward trend on March 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for BSX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for BSX just turned positive on February 24, 2026. Looking at past instances where BSX's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in of 351 cases, the price rose further within the following month. The odds of a continued upward trend are .
BSX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.403) is normal, around the industry mean (13.708). P/E Ratio (37.062) is within average values for comparable stocks, (41.238). Projected Growth (PEG Ratio) (0.799) is also within normal values, averaging (1.604). BSX's Dividend Yield (0.000) is considerably lower than the industry average of (0.020). P/S Ratio (5.353) is also within normal values, averaging (35.235).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of medical devices
Industry MedicalNursingServices
Advertisement